Bangladesh vs Myanmar: Average cost of multi drug-resistant tuberculosis treatment
Bangladesh
466 constant 2022 US$
in 2024
Myanmar
468 constant 2022 US$
in 2024
Bangladesh rank
81st
Myanmar rank
80th
Average cost of multi drug-resistant tuberculosis treatment over time
- Bangladesh
- Myanmar
How they compare
Myanmar currently reports 468 constant 2022 US$ against 466 constant 2022 US$ in Bangladesh, a difference of 2 constant 2022 US$.
The two have swapped places 1 time across 8 shared years of data; in 2017 it was Bangladesh ahead.
Bangladesh ranks 81st and Myanmar ranks 80th of 92 countries.
Across the 2 decades both report, Bangladesh averaged higher in 1 and Myanmar in 1.
Head to head by decade
| Decade | Bangladesh | Myanmar | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,374 constant 2022 US$ | 1,184 constant 2022 US$ | 190 constant 2022 US$ | Bangladesh |
| 2020s | 769 constant 2022 US$ | 944 constant 2022 US$ | 175 constant 2022 US$ | Myanmar |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Bangladesh or Myanmar?
- Myanmar, at 468 constant 2022 US$ against 466 constant 2022 US$ in Bangladesh as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Bangladesh and Myanmar?
- 2 constant 2022 US$, with Myanmar ahead.
- How many years of comparable data are there for Bangladesh and Myanmar?
- 8 years are reported by both, from 2017 to 2024.
- How do Bangladesh and Myanmar rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Bangladesh ranks 81st and Myanmar ranks 80th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.